Enterprise Stakeholders

The Global HIV Vaccine Enterprise is a unique, international alliance of more than 30 independent research, funding, advocacy and stakeholder organizations and governments, engaged in unprecedented collaboration to speed the development of a safe and effective HIV vaccine. 

HIV vaccine research has progressed further and faster in the last few years than at any time since the epidemic began.  This new and highly promising era in research is a result of the outstanding achievements of Enterprise stakeholders, many of which are reflected in the Enterprise 2008 - 2010 Report of Activities.

Enterprise Stakeholders Include: African AIDS Vaccine Partnership (AAVP) AVAC: Global Advocacy for HIV Prevention  AIDS Vaccine for Asia Network (AVAN) Bill & Melinda Gates Foundation Canadian HIV Vaccine Initiative (CHVI) Center for HIV/AIDS Vaccine Immunology (CHAVI) Chinese AIDS Vaccine Initiative Collaboration for AIDS Vaccine Discovery (CAVD) Department for International Development (DFID) European Commission Europrise EuroVac GlaxoSmithKline HIV Vaccine Trials Network (HVTN) International AIDS Vaccine Initiative (IAVI) Merck & Co. Inc. National Agency for AIDS Research (ANRS) National Institute of Allergy and Infectious Diseases (NIAID) Novartis Vaccines sanofi pasteur South African AIDS Vaccine Initiative (SAAVI) U.S. Military HIV Research Program (MHRP) UNAIDS USAID Vaccine Research Center (VRC) Wellcome Trust World Health Organization (WHO)